ConductScience.org, home

Paper32192578

COVID-19: consider cytokine storm syndromes and immunosuppression.

Mehta P and 6 others. Lancet, 2020. Cited by 6,656 papers, by iCite.

Cite this record

ConductScience Library. COVID-19: consider cytokine storm syndromes and immunosuppression. Papers, record 32192578. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32192578

Download JSON
Disease
COVID-19540 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
COVID-19: consider cytokine storm syndromes and immunosuppression.
PubMed
Journal
Lancet
PubMed
Year
2020
PubMed
Publication types
Letter
PubMed
Citations, by iCite
6,656
iCite
Relative citation ratio, by iCite
387
iCite
Revised in PubMed
2022-12-07
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mehta PPuja
2McAuley DFDaniel F
3Brown MMichael
4Sanchez EEmilie
5Tattersall RSRachel S
6Manson JJJessica J
7HLH Across Speciality Collaboration, UKGroup

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BetacoronavirusMajor topic
Coronavirus InfectionsMajor topic
CytokinesMajor topic
Immunosuppression TherapyMajor topic
InflammationMajor topic
Pneumonia, ViralMajor topic
Antirheumatic Agents
COVID-19
Humans
Immunization, Passive
Immunoglobulins, Intravenous
Immunosuppressive Agents
Pandemics
SARS-CoV-2
Steroids
COVID-19 Drug Treatment
COVID-19 Serotherapy

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Wellcome TrustUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials45

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04328480The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.ResultsClinicalTrials.gov
NCT04339634Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With PolypharmacyBackgroundClinicalTrials.gov
NCT04340921The Role of Adaptive Immunity in COVID-19 Associated Myocardial InjuryBackgroundClinicalTrials.gov
NCT04343755Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 InfectionBackgroundClinicalTrials.gov
NCT04345679Anti COVID-19 Convalescent Plasma TherapyBackgroundClinicalTrials.gov
NCT04352803Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 DiseaseBackgroundClinicalTrials.gov
NCT04353674Modulation of Hyperinflammation in COVID-19ResultsClinicalTrials.gov
NCT04358926Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)BackgroundClinicalTrials.gov
NCT04361526Pilot Study on Cytokine Filtration in COVID-19 ARDSBackgroundClinicalTrials.gov
NCT04366232Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 InflammationResultsClinicalTrials.gov
NCT04374149Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSBackgroundClinicalTrials.gov
NCT04377503Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19BackgroundClinicalTrials.gov
NCT04379037Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized PatientsBackgroundClinicalTrials.gov
NCT04400929Using GM-CSF as a Host Directed Therapeutic Against COVID-19BackgroundClinicalTrials.gov
NCT04407182Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19BackgroundClinicalTrials.gov
NCT04414059Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised PatientsBackgroundClinicalTrials.gov
NCT04420260Primary Prevention of Infection by COVID-19 in WorkersBackgroundClinicalTrials.gov
NCT04438629Evaluation of Immune Response in COVID-19 PatientsBackgroundClinicalTrials.gov
NCT04454372Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)ResultsClinicalTrials.gov
NCT04456413Convalescent Plasma as Treatment for Subjects With Early COVID-19 InfectionBackgroundClinicalTrials.gov

See all 45 trialsDownload CSV of trials

Comments and corrections7

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Associated dataset34756322Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.https://conductscience.org/library/papers/34756322PubMed
Comment in32220278Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?https://conductscience.org/library/papers/32220278PubMed
Comment in32238976Cytokine storms in COVID-19 cases?https://conductscience.org/library/papers/32238976PubMed
Comment in32378064Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms.https://conductscience.org/library/papers/32378064PubMed
Comment in32423585Is the HScore useful in COVID-19?https://conductscience.org/library/papers/32423585PubMed
Comment in32631836Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?https://conductscience.org/library/papers/32631836PubMed
Comment in32668194Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease.https://conductscience.org/library/papers/32668194PubMed

Download CSV of comments and corrections

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132032529Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.Lancet2020https://conductscience.org/library/papers/32032529PubMed
224290661Adult haemophagocytic syndrome.Lancet2014https://conductscience.org/library/papers/24290661PubMed
330766533Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis.Front Immunol2019https://conductscience.org/library/papers/30766533PubMed
432043983Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.Lancet2020https://conductscience.org/library/papers/32043983PubMed
524782338Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.Arthritis Rheumatol2014https://conductscience.org/library/papers/24782338PubMed
626836913Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis.Chest2016https://conductscience.org/library/papers/26836913PubMed
732125452Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.Intensive Care Med2020https://conductscience.org/library/papers/32125452PubMed
831986264Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet2020https://conductscience.org/library/papers/31986264PubMed
926584195Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.Crit Care Med2016https://conductscience.org/library/papers/26584195PubMed

Download CSV of references

Cited by5,536

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6,656 citations.

PMIDTitleJournalYearIn PapersSource
42975773In vitro antioxidant, anti-inflammatory, antifungal, and anti-HCoV-229E activities of Jatropha integerrima leaf and stem bark extract and in vivo evaluation of its intravenous SNEDDS in a mouse model.Daru2026https://conductscience.org/library/papers/42975773PubMed
42931232Lethal Viral Sepsis/Septic Shock in Getah Virus-Infected Ifnar1-/- Mice.Pathogens2026https://conductscience.org/library/papers/42931232PubMed
42930509Clinical Outcomes and Hospital Resource Utilization Among Patients with Sepsis and COVID-19 Infection: Insights from the United States National Inpatient Sample Analysis, 2020-2022.Infect Dis Rep2026https://conductscience.org/library/papers/42930509PubMed
42903466SARS-CoV-2: Possible role in children with acute hepatitis of unknown origin.Hlife2023https://conductscience.org/library/papers/42903466PubMed
42872078Exploring the Link Between SARS-CoV-2 RT-PCR Cycle Threshold, Clinical Characteristics, and Laboratory Results in Hospitalized COVID-19 Patients With Neurological and Autoimmune Conditions.Med J Islam Repub Iran2025https://conductscience.org/library/papers/42872078PubMed
42840777Triptolide-loaded MSC membrane nanoparticles with enhanced pulmonary accumulation for the treatment of acute lung injury: from network pharmacology to experimental validation.Int J Pharm X2026https://conductscience.org/library/papers/42840777PubMed
42837035Generation of DFNA5-deficient chickens reveals a species-specific role of pyroptosis in avian antiviral immunity.Transgenic Res2026https://conductscience.org/library/papers/42837035PubMed
42811300Hyperinflammatory nutritional index as an exploratory combined inflammatory and nutritional marker: associations with cytokines and β2-microglobulin in COVID-19.BMC Infect Dis2026https://conductscience.org/library/papers/42811300PubMed
42796098Safety and Changes in Health-Related Quality of Life After Epidural Oxygen Injection for Long COVID/Post-COVID Syndrome: A Multicenter Retrospective Study.J Clin Med2026https://conductscience.org/library/papers/42796098PubMed
42767748Defining the preadmission factors that modify risk of acute complications, survival and long-term recovery from COVID-19: prospective, longitudinal, multisite, cohort study based in England.BMJ Open2026https://conductscience.org/library/papers/42767748PubMed
42757067Glutathione Peroxidase (GPx) and Glutathione Reductase Gene Expression as Key Factors in the Glutathione System, in Oxidative Stress Pathways in Patients with COVID-19.Tanaffos2025https://conductscience.org/library/papers/42757067PubMed
42756421Adaptive bandwidth of immunity: a systems-level framework for understanding immune regulation across time.Front Immunol2026https://conductscience.org/library/papers/42756421PubMed
42741025Sex and age are associated with host immune responses and multi-organ dysfunction in hospitalized patients with COVID-19.Front Public Health2026https://conductscience.org/library/papers/42741025PubMed
42707763Repair and regeneration across the lifespan: an ontogenetic perspective.Front Aging2026https://conductscience.org/library/papers/42707763PubMed
42685097Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study.PLoS One2026https://conductscience.org/library/papers/42685097PubMed
42655643The Environmental Polycyclic Aromatic Hydrocarbon (PAH) Benzo[a]pyrene (BP) Alters SARS-CoV-2 Pathogenesis in a Mouse Model of Disease.Viruses2026https://conductscience.org/library/papers/42655643PubMed
42650274Phytochemical Profiling and Proteomic Insights into the Anti-Inflammatory Effects of Jing Guan Fang in LPS-Stimulated Macrophages.Antioxidants (Basel)2026https://conductscience.org/library/papers/42650274PubMed
42589551Neurodegenerative and Cognitive Consequences of Long COVID.Int J Mol Sci2026https://conductscience.org/library/papers/42589551PubMed
42553313Multiscale bone remodeling in COVID-19: from osteoimmune signaling to structural and mechanical impairment.Front Bioeng Biotechnol2026https://conductscience.org/library/papers/42553313PubMed
42553204Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications.Front Immunol2026https://conductscience.org/library/papers/42553204PubMed

See all 5,536 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs6

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
COLCHICINECHEMBL107Results1https://conductscience.org/library/drugs/CHEMBL107ChEMBL
ANAKINRACHEMBL1201570Results1https://conductscience.org/library/drugs/CHEMBL1201570ChEMBL
CYCLOSPORINECHEMBL160Results1https://conductscience.org/library/drugs/CHEMBL160ChEMBL
RUXOLITINIBCHEMBL1789941Results1https://conductscience.org/library/drugs/CHEMBL1789941ChEMBL
CLAZAKIZUMABCHEMBL2108589Results1https://conductscience.org/library/drugs/CHEMBL2108589ChEMBL
ASPIRINCHEMBL25Results1https://conductscience.org/library/drugs/CHEMBL25ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32192578

GET https://conductscience.org/api/papers/v1/32192578/trials?page=2